--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results--
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2024 | $35.00 | Overweight | Piper Sandler |
| 5/17/2024 | $14.00 | Outperform | Oppenheimer |
| 1/5/2024 | $8.00 | Overweight | Cantor Fitzgerald |
| 10/26/2022 | $15.00 | Buy | Ladenburg Thalmann |
| 1/31/2022 | $14.00 → $18.00 | Buy | HC Wainwright & Co. |
| 10/11/2021 | $9.00 → $14.00 | Buy | HC Wainwright & Co. |
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the third quarter ended September 30, 2024, after the market close on Wednesday, November 13, 2024. Management will then host a webcast and conference call at 4:30 p.m. ET on November 13. Title:Capricor Therapeutics Third Quarter 2024 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, November 13, 2024Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 680
-BLA to be Supported by Existing and Natural History Cardiac Data as Discussed with the FDA- -Initial Label Would Include All Patients with Cardiomyopathy Associated with Duchenne Muscular Dystrophy- -Rolling Submission Planned to Commence in October 2024- -Internal GMP Manufacturing Established to Support BLA and Commercialization- -Investor Webcast Today at 8:30 a.m. ET- SAN DIEGO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today, following recent meetings with the U.S. Food and Drug Administration (FDA), its intent to file
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will host an investor webcast on Tuesday, September 24, 2024 at 8:30 a.m. ET to provide an update on its Duchenne muscular dystrophy (DMD) program. The update will consist of the latest regulatory updates following the Company's recent meetings with the U.S. Food and Drug Administration (FDA). Webcast Details Capricor will host a conference call and webcast at 8:30 a.m. ET on Tuesday, September 24, 2024. To participate in the conference call, please dial 1-800-71
SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the European Medicines Agency (EMA) has granted both Orphan Drug and Advanced Therapy Medicinal Product (ATMP) designations to its lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD). The Orphan Drug designation provides Capricor with several benefits that support the development of deramiocel in Europe, including market exclusivity for 10 years if approval is granted and substantially reduced regulatory fees. The ATMP designation prov
Announced intent to file a biologics license application (BLA) for deramiocel to treat all patients with DMD-cardiomyopathy Rolling BLA submission initiated in October 2024 with full submission expected by year-end 2024Company anticipates potential PDUFA date in second half of 2025Announced signing of binding term sheet with Nippon Shinyaku for European expansion and commercialization of deramiocel; potential milestones from combined agreements would total approximately $1.5 billion payable to Capricor Reported positive long-term data from HOPE-2 OLE trial at 2024 World Muscle Society CongressStealthX™ exosome platform expanded to include PMO loading and targeting for the treatment of DMD pr
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that an abstract featuring new preclinical data highlighting the therapeutic potential of its StealthX™ exosome platform technology is being presented at the 2024 American Association of Extracellular Vesicles Annual Meeting taking place in Houston, Texas from November 10-13, 2024. The findings highlight a potential exosome-based approach for the treatment of Duchenne muscular dystrophy (DMD) by delivering phosphorodiamidate morpholino oligomers (PMOs). "We continue to bui
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
3 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
Piper Sandler initiated coverage of Capricor Therapeutics with a rating of Overweight and set a new price target of $35.00
Oppenheimer initiated coverage of Capricor Therapeutics with a rating of Outperform and set a new price target of $14.00
Cantor Fitzgerald initiated coverage of Capricor Therapeutics with a rating of Overweight and set a new price target of $8.00
SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
Analysts' ratings for Capricor Therapeutics (NASDAQ:CAPR) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 1 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $27.83, a high estimate of $40.00, and a low estimate of $8.00. A negative
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40 price target.
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024.
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
10-Q - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
EFFECT - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024. "We are thrilled to be joining the Russell 2000® Index, a testament to our Company's progress across our pipeline marked by significant advancements in our lead program for the treatment of Duchenne muscular dystrophy," said Linda Marbán, Ph.D., Capricor's chief executive officer. "This milestone reflects Ca
SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately. Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry. "It is a pleasure to welcome Mike to our Board of Directors, who has an extraor
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment of Philip J. Gotwals, Ph.D., to its Board of Directors, effective immediately. Dr. Gotwals, most recently the Global Head, Vice President of Business Development and Licensing at Novartis Institutes for Biomedical Research, brings his strategic vision for research, innovation for drug development and valuable industry experience to the Company. "It is a pleasure to welcome Philip to our Board of Directo